Literature DB >> 1624677

Evaluation of hypothalamic-pituitary function in patients with thalassemia major.

L Danesi1, M Scacchi, M De Martin, A Dubini, P Massaro, A T Majolo, F Cavagnini, E E Polli.   

Abstract

The increased survival of patients with thalassemia major, made possible by more adequate therapeutic regimens, has emphasized the importance of the endocrine abnormalities often associated with this disease. In twelve thalassemic patients, we evaluated the hypothalamic-pituitary function by measuring plasma levels of anterior pituitary hormones under basal conditions and in the course of provocative tests. An impairment of growth hormone (GH) secretion was demonstrated in a considerable proportion (7/12) of these patients. In some of them failure of GH response to insulin-hypoglycemia and normal hormone rise after growth hormone-releasing hormone indicate a hypothalamic defect. A defective prolactin secretion was observed in the female hypogonadic but not in the male thalassemic patients. This abnormality appears to be dependent on estrogen deficiency rather than on a hypothalamic-pituitary dysfunction. In our series a high prevalence (8/12) of hypogonadism was also noticed. In these cases, the low gonadotropin levels and their unresponsiveness to gonadotropin-releasing hormone are compatible with a hypothalamic and/or pituitary damage. Lastly, the enhanced ACTH responses to the stimuli associated to a reduced cortisol release suggest the existence, in these patients, of a diminished adrenocortical reserve. On the whole, this study has shown several derangements of the hypothalamic-pituitary function in thalassemia. This emphasizes the need for careful endocrine surveillance in this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1624677     DOI: 10.1007/BF03348701

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  Neurosecretory dysfunction of growth hormone secretion in thalassemia major.

Authors:  N Shehadeh; A Hazani; M C Rudolf; I Peleg; A Benderly; Z Hochberg
Journal:  Acta Paediatr Scand       Date:  1990 Aug-Sep

Review 2.  Endocrine abnormalities in thalassemia.

Authors:  C Vullo; V De Sanctis; M Katz; B Wonke; A V Hoffbrand; B Bagni; T Torresani; G Tolis; M Masiero; A Di Palma
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

3.  Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major.

Authors:  C Pintor; S G Cella; P Manso; R Corda; C Dessĭ; V Locatelli; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1986-02       Impact factor: 5.958

4.  Growth and sexual maturation in thalassemia major.

Authors:  C Borgna-Pignatti; P De Stefano; L Zonta; C Vullo; V De Sanctis; C Melevendi; A Naselli; G Masera; S Terzoli; V Gabutti
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

5.  Prolactin responsiveness to TRH and metoclopramide in thalassaemia.

Authors:  I M Spitz; H Landau; V Gross; S Trestian; Z Palti; E Rachmilewitz
Journal:  Clin Endocrinol (Oxf)       Date:  1982-03       Impact factor: 3.478

6.  Pituitary and thyroid insufficiency in thalassaemic haemosiderosis.

Authors:  D P Livadas; K Sofroniadou; A Souvatzoglou; M Boukis; L Siafaka; D A Koutras
Journal:  Clin Endocrinol (Oxf)       Date:  1984-04       Impact factor: 3.478

7.  Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion.

Authors:  C A Sklar; L Q Lew; D J Yoon; R David
Journal:  Am J Dis Child       Date:  1987-03

8.  Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect.

Authors:  J Leger; R Girot; H Crosnier; M C Postel-Vinay; R Rappaport
Journal:  J Clin Endocrinol Metab       Date:  1989-08       Impact factor: 5.958

9.  Depressed serum somatomedin activity in beta-thalassemia.

Authors:  P Saenger; E Schwartz; A L Markenson; J H Graziano; L S Levine; M I New; M W Hilgartner
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

10.  Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major.

Authors:  M Bozzola; J Argente; M Cisternino; A Moretta; A Valtorta; I Biscaldi; M Donnadieu; D Evain-Brion; F Severi
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

View more
  5 in total

1.  High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment.

Authors:  S Mariotti; A Loviselli; S Murenu; F Sau; L Valentino; A Mandas; S Vacquer; E Martino; A Balestrieri; M E Lai
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 3.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

4.  Growth hormone secretion in polytransfused prepubertal patients with homozygous beta-thalassemia. Effect of long-term recombinant GH (recGH) therapy.

Authors:  A Masala; M M Atzeni; S Alagna; D Gallisai; C Burrai; M G Mela; P P Rovasio; P Gallo
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

5.  Low-dose Synachten test with measurement of salivary cortisol in adult patients with β-thalassemia major.

Authors:  Alberto G Ambrogio; Leila Danesi; Marina Baldini; Raffaella Radin; Elena Cassinerio; Giovanna Graziadei; Nadia Mirra; Emanuela D'Angelo; Alessia Marcon; Marta Mancarella; Alessandra Orsatti; Federico Bonetti; Massimo Scacchi; Maria Domenica Cappellini; Luca Persani; Francesca Pecori Giraldi
Journal:  Endocrine       Date:  2018-03-23       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.